Publications
Selected Publications
Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D and Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82(3): 292-303, 2012.
Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CRJ and Burns KD. Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes. PLoS ONE. 2012;7(5):e37649.
Xiao F, Zimpelmann J, Agaybi S, Gurley SB, Puente L and Burns KD. Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One. 2014 Jan 15:9(1):e85958.doi:10.1371.
Burger D, Viñas J, Akbari S, Dehak H, Knoll W, Gutsol A, Touyz RM, Allan DS and Burns KD. Human endothelial colony forming cells protect against acute kidney injury: role of exosomes. Am J Pathol 185(8):2309-23, 2015. Senior corresponding author, Funded by KFOC.
Viñas Jose L, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, Gutsol A, Carter A, Allan DS, Burns KD. Transfer of MicroRNA-486-5p from Human Endothelial Colony Forming Cell-derived Exosomes in Ischemic Kidney Injury. Kidney Int (in press).
All Other Publications
Publications since 2009
65. Zimpelmann J, Burns KD. Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 296: F337-F346, 2009. Funded by CIHR, KFOC, Senior corresponding author.
66. Cherney DZ, Scholey JW, Zhou J, Zimpelmann J, Kennedy C, Burns KD, Lai V and Miller JA. Endothelial Nitric Oxide Synthase Gene Polymorphisms and the Renal Hemodynamic Response to L-Arginine. Kidney Int 75: 327-332, 2009.
67. Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, Santos RA, Touyz RM and Burns KD. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 24: 1766-73, 2009. Funded by CIHR, KFOC. Senior corresponding author.
68. Seedek M, Hébert RL, Kennedy CR, Burns KD and Touyz RM. Molecular mechanisms of hypertension – role of Nox-family NADPH oxidase. Curr Opin Nephrol Hypertens 18:122-127, 2009.
69. Prasad GV, Ruzicka M, Burns KD, Tobe SW and Lebel M. Hypertension in dialysis and kidney transplant patients. Can J Cardiol 25: 309-14, 2009. Major contribution to writing..
70. Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McKay DW, Wilson T, Penner B, Burgess E, McAlister FA, Bolli P, Hill MD, Mahon J, Myers MG, Abbott C, Schiffrin E, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Bell C, Burns KD, Ruzicka M, Campbell NRC, Vallee M, Prasad R, Lebell M and Tobe SW. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 25: 279-86, 2009.
71. Khan NA, Hemmelgarn B, Herman RJ, Bell CM, T Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ and Tobe S. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Can J Cardiol 25: 287-98, 2009.
72. Burns KD and Li N. Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 296:F666, 2009 (letter to the editor).
Corresponding author.
73. Dilauro, M and Burns KD. Angiotensin-(1-7) and its effects in the Kidney. Scientific World Journal. 30:522-35, 2009. Funded by CIHR, KFOC. Senior corresponding author.
74. Hadizad T, Kirkpatrick SA, Mason S, Burns KD, Beanlands RS and DaSilva JN. "Novel O-[11C]methylated derivatives of candesartan as angiotensin II AT1 receptor imaging ligands: Radiosynthesis and ex vivo evaluation in rats. Bioorg Med Chem 17: 7971-7977, 2009.
75. Hiremath S, Doucette SP, Richardson R, Chan K, Burns KD and Zimmerman D. Left Ventricular Growth after one year of hemodialysis does not correlate with arterio-venous access flow: A prospective cohort study. Nephrol Dial Transplant 25: 2656-2661, 2010. Major contribution to manuscript.
76. Quinn RR, Hemmelgarn BR, Padwal RS, Myers MG, Cloutier L, Bolli P, McKay DW, Khan NA, Hill MD, Mahon J, Hackam DG, Grover S, Wilson T, Penner B, Burgess E, McAlister FA, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NRC, Vallee M, Prasad GVR, Lebel M and Tobe SW for the Canadian Hypertension Education Program. The 2010 Canadian Hypertension education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 26: 241-248, 2010.
77. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NRC, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JMO, Moe GW, Howeltt JG, Trudeau L, Bacon SL, Petrella RJ, Milot A. Stone JA, Drouin D, Bolanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylpchuk G, Burgess ED, Burns KD, Vallee M, Prasad GVR, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA and Tobe SW. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Can J Cardiol 26: 249-258, 2010.
78. Dilauro, M, Zimpelmann J, Robertson S, Genest D and Burns KD. The Effect of ACE2 and Angiotensin-(1-7) in a Mouse Model of early Chronic Kidney Disease. Am J Physiol – Renal Physiol 298:1523-1532, 2010. Funded by CIHR, KFOC. Senior corresponding author.
79. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CRJ, Burns KD, Touyz RM and Hébert RL. Critical role of Nox4-based NADPH oxidase in glucose-induced stress in the kidney-implications in diabetic nephropathy. Am J Physiol Renal Physiol 299: F1348-F1358, 2010. Funded by KFOC, Pfizer Award. Major contribution to study design, writing.
80. Burns KD, Wolfs W, Bélanger P, McLaughlin K and Levin A. The KRESCENT Program: An initiative to match supply and demand for kidney research in Canada. Clin Invest Med 33: E356-E367, 2010. Senior corresponding author.
81. LeBlanc SE, Atanya M, Burns KD and Munger R. Quantitative Impact of Small Angle Forward Scatter on Whole Blood Oximetry Using a Beer-Lambert Absorbance Model. Analyst 136: 1637-43, 2011.
82. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Campbell TS, Lindsay MP, Herman RJ, Larochelle P, Feldman RD, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW: Canadian Hypertension Education Program. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 27: 415-433, 2011
83. Mendelssohn DC, Curtis B, Yeates K, Langlois S, MacRae JM, Semeniuk LM, Camacho F, and McFarlane P for the STARRT Study Investigators including Burns KD. Suboptimal initiation of dialysis with and without early referral to a nephrologist. Nephrol Dial Transplant 26: 2959-2965, 2011.
84. Chung Y, Abou-Nassar K, Li Y, Filion L, Watpool I, McArdle T, McIntyre L, Ramsay T, Cheesman J, Touyz R, Burns KD and Allan DS. Vascular progenitor recruitment in critically ill patients with acute kidney injury. Clin Invest Med 34: E304-E310, 2011. Major contribution to research protocol, and writing of manuscript.
85. Hladenuwich M, Lai V, Miller J, Cherney D, Burns KD, Zimpelmann J, O'Brien T, Gandhi S, Kiss A, Kingdom J, Odutayo A. Postpartum Assessment of the Renin Angiotensin System in Women with Previous Severe, Early-Onset Pre-Eclampsia. J Clin Endocrinol Metab 96: 3517-24, 2011.
86. Hale TM, Robertson SJ, Burns KD and deBlois D. Short-term ACE Inhibition Confers Long-term Protection against Target Organ Damage. Hypertens Res Jun;35(6):604-10, 2012. Funded by CIHR, KFOC. Major contribution to research design and writing.
87. Labonté L, Li Y, Addison C, Brand M, Javidnia H, Corsten MJ, Burns KD and Allan D.
Distinct profile of vascular progenitor attachment to extracellular matrix proteins in cancer patients. Clin Invest Med 35(2):E86-95, 2012.
88. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D and Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82(3): 292-303, 2012. Funded by CIHR, KFOC. Senior corresponding author.
89. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD and Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes-associated obesity and vascular dysfunction. Hypertens May 59(5):1069-78, 2012.
90. Burger D, Gutsol A, Carter A, Allan DS, Touyz RM and Burns KD. Human Cord Blood CD133+ Cells Exacerbate Ischemic Acute Kidney Injury in Mice. Nephrol Dial Transplant. 27(10):3781-9, 2012. Senior corresponding author.
91. Burns KD and Hiremath S. Urinary angiotensinogen as a biomarker of chronic kidney disease: ready for prime time? (Invited Editorial. Nephrol Dial Transplant, 27(8):3010-3013.
92. Zimmerman D and Burns KD. Angiotensin-(1-7) in Kidney Disease: A review of the controversies. Clin Sci (Lond) 123 (6):333-46, 2012. Funded by KFOC, CIHR. Senior corresponding author.
93. Briet M and Burns KD. Chronic Kidney Disease and Vascular Remodeling: Molecular Mechanisms and Clinical Implications. Clin Sci (Lond) 123(7):399-416, 2012.
94. Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CRJ and Burns KD. Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes. PLoS ONE. 2012;7(5):e37649. Funded by KFOC, CIHR. Senior corresponding author.
95. McCormick B, Davis J and Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 60(4):626-8, 2012.
96. Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NR, Reid D, Poirier L, Tobe SW; Canadian Hypertension Education Program. The 2012 Canadian Hypertension Education Program Recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 28(3):270-87, 2012
97. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm KA, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM. Renoprotective effects of a novel Nox ¼ inhibitor in a mouse model of type 2 diabetes. Clin Sci (Lond). 124:191-202, 2013.
98. Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS. The 2013 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2013 29(5):528-42.
99. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD and Batlle D. Regulation of Urinary ACE2 in Diabetic Mice. Am J Physiol Renal Physiol. 2013;305(4):F600-11.
100. Xiao F, Zimpelmann J, Agaybi S, Gurley SB, Puente L and Burns KD. Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells. PLoS One. 2014 Jan 15:9(1):e85958.doi:10.1371. Funded by CIHR, KFOC. Senior corresponding author.
101. Abujrad H, Mayne J, Ruzicka M, Cousins M, Raymond A, Cheesman J, Taljaard M, Sorisky A, Burns KD and Ooi, TC. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 Levels. Atherosclerosis. 233(1):123-129, 2014.
102. Burger D, Thibodeau JF, Holterman C, Burns KD, Touyz R and Kennedy C. Urinary podocyte microparticles identify prealbuminuric diabetic glomerular injury. J Am Soc Nephrol 2014 Mar 27 (Epub ahead of print). Major contribution to study design writing.
103. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer M, Vallée M, Prasad GV, Lebel M, McLean D, Arnold J Malcolm, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA, Drouin D, Lavoie KL, Clamrre-Cliché M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M, Reid D, Tobe SW, Padwal RS and Poirier L for the Canadian Hypertension Education Program. The 2014 Canadian Hypertension Education Program (CHEP) Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension. Can J Cardiol. 2014 May:30(5) 485-501.
104. Zimmerman DL, Ruzicka M, Hebert P, Fergusson D, Touyz RH and Burns KD. Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. PLoS One. 2014 May 29;9(5):e97135.doi:10.1371.
105. Shaw J, Shetty P, Burns KD and Knoll G. The therapeutic potential of C-peptide in kidney disease: a protocol for a systematic review and meta-analysis. Systematic Reviews. In Press 2014, 3:43 doi.10.1186/2046-4053-3-43
106. Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M and Burns KD. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Letter to the Editor – Kidney Int 86(5):1057-8, 2014. Funded by CIHR.
107. Cherney DZ, Xiao F, Zimpelmann J, Har RL, Lai V, Scholey JW, Reich HN and Burns KD. Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. Can J Physiol Pharmacol 92(8):703-6, 2014. Funded by CIHR.
108. Clark EG, Knoll G, Bugeja A, Burns KD and Scofield RH. Lupus after kidney donation to an affected male relative. Transplantation 99(4):e27-28, 2015.
109. Zimmerman DL, Zimpelmann J, Xiao F, Gutsol A, Touyz R, and Burns KD. The effect of Ang-(1-7) in mouse unilateral ureteral obstruction. Am J Pathol 185(3):729-40, 2015. Senior corresponding author, funded by CIHR.
110. Clark EG and Burns KD. Pincer nails following arteriovenous fistula creation. Kidney Int, 88(4):918, 2015.
111. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliché M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV , Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PH, Oh P, Hegele RAKhara M, WilsonTW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath W, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Gregoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Padwal RS, Poirier L, for the Canadian Hypertension Education Program. The 2015 Canadian Hypertension Education Program (CHEP) Recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 31(5):549-68, 2015.
112. Shaw J, Shetty P, Burns KD, Fergusson D and Knoll G. C-Peptide as a therapy for kidney disease: a systematic review and meta-analysis. PLOS One 10(5):e0127439, 2015.
113. Nasrallah R, Z Hassouneh R, Zimpelmann J, Karam AJ, Thibodeau JF, Burger D, Burns KD, Kennedy CR and Hébert R. Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. Lab Invest 95: 1044-55, 2015.
114. Burger D, Viñas J, Akbari S, Dehak H, Knoll W, Gutsol A, Touyz RM, Allan DS and Burns KD. Human endothelial colony forming cells protect against acute kidney injury: role of exosomes. Am J Pathol 185(8):2309-23, 2015. Senior corresponding author, Funded by KFOC.
115. Burger D, U. Erdbrugger and Burns KD. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and acute kidney injury. Letter to the Editor, Kidney Int 88(4):915, 2015.
116. Akbari A, Hladunewich M, Burns KD, Felipe M, Abou Arkoub R, Brown P and Hiremath S.
Circulating angiogenic factors in a pregnant woman on intensive hemodialysis: A case
report. Can J Kidney Health and Disease Feb 23;3:7. doi: 10.1186/s40697-016-0096-7. eCollection 2016.
117. Rodriguez RA, Cronin C, Ramsay T, Zimmerman D, Ruzicka M, and Burns KD. Reproducibility of Carotid-Femoral Pulse-Wave Velocity in End-Stage Renal Disease Patients: Methodological considerations. Can J Kidney Health and Disease, Apr 1;3:20. doi: 10.1186/s40697-016-0109-6. eCollection 2016.
118. Hassouneh R, Nasrallah R, Zimpelmann J, Gutsol A, Ghossein J, Eckert D, Burns KD
and Hébert RL. PGE2/EPS inhibits vasopressin-stimulated water reabsorption and
contributes to diabetic dysfunction in mice. Diabetologia 59(6):1318-28, 2016.
119. Xiao F, Zimpelmann J, Burger D, Kennedy CRJ, Hebert RL, and Burns KD. Protein Kinase C-δ Mediates Shedding of Angiotensin-Converting Enzyme 2 from Proximal Tubular Cells. Front Pharmacol (Cardiovascular and Smooth Muscle Pharmacology) 7:146. doi: 10.3389/fphar.2016.00146 eCollection, 2016.
120. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol May;32(5):569-88, 2016.
121. Viñas Jose L, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, Gutsol A, Carter A, Allan DS, Burns KD. Transfer of MicroRNA-486-5p from Human Endothelial Colony Forming Cell-derived Exosomes in Ischemic Kidney Injury. Kidney Int (in press).
122. Rodriguez RA, Shea B, Hae R, Burns KD. The Impact of Intervention Strategies that Target Arterial Stiffness in End-Stage Renal Disease: A Systematic Review Protocol. Syst Rev 5(1):118. doi: 10.1186/s13643-016-0286-5, 2016.
PubMed Listings
